PHILADELPHIA, Pa., Oct. 12, 2026 – Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough ...

Hello from Philadelphia, PA! We could not be more thrilled that, after years and years, we have finally kicked off our inaugural Breakthrough T1D Clinical & Research Congress (CRC). This ...

Breakthrough T1D’s first-ever Clinical and Research Congress (CRC), focused entirely on type 1 diabetes (T1D), has come to a ...

It’s a rainy day in Philadelphia, but the mood at CRC 2026 could not be sunnier! The attendees were positively buzzing (seriously) with how timely and impactful this meeting is. It’s the right time ...

Read all the updates from day 2 of Breakthrough T1D's Clinical and Research Congress focused entirely on type 1 diabetes.

As a chronic health condition, type 1 diabetes (T1D) is a full-time job. Getting sick can throw a wrench right through your management.

Heart and kidney complications remain a major concern for people living with type 1 diabetes (T1D). While there are some therapies available to reduce the risk of these complications, the T1D ...

Event Will Convene Global Leaders to Shape the Future of Type 1 Diabetes in Philadelphia October 9-11 PHILADELPHIA, Pa., Oct. 5, 2026 – Breakthrough T1D, formerly JDRF, the leading global type 1 ...

Sana’s novel cell therapy approach is designed to help transplanted islet cells evade immune attack while continuing to produce insulin. The strategy uses gene editing to create hypoimmune islet cells ...

Jessie Stover is the Development Manager at Breakthrough T1D’s Indiana Chapter. Stover was born and raised in Evansville, Indiana, and she now lives in Indianapolis with her two cats, Milo and Zuko.

In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for ...